Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
Seamus Mulligan bought 100,000 shares of JAZZ on 9 May at $99.71 per share, worth a total of $10.0M. They now own 100,000 JAZZ shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
